Appears that VERS has a lot on its plate in the near future.
This upcoming conference in which they have a keynote presentation on the agenda should give better insight into their drug development. At this stage it looks very positive...one can only hope!
"Strategic Research Institute Release: Resistance In Fluroquinolones To Headline 8th Annual Antibacterial Drug Discovery And Development Summit, March 24-25, 2003, In Princeton, New Jersey
PRINCETON, N.J., Feb. 20 /PRNewswire/ -- Antibacterial scientists from the international community will be convening in Princeton, NJ on March 24-25, 2003 to discuss the latest research advances at the discovery, pre-clinical, and clinical stages at the 8th Annual, "Antibacterial Drug Discovery & Development Summit," announces Strategic Research Institute.
The meeting will be broken into three discrete sections: 1. New Discovery & Research, 2. Preclinical & Clinical Development, and 3. Emerging Technologies.
Highlights of the meeting include:
Keynote: "Resistance in Fluroquinolones: Mechanisms & Epidemiology," David Hooper, M.D., MASS GENERAL HOSPITAL
"Why is Big Pharma Getting Out of Antibacterial Research?" WYETH RESEARCH
"The Therapeutic Potential of the New Ketolides, Cethromycin and Telithromycin" ABBOTT LABORATORIES
"A Bacterial Peptide Deformylase Inhibitor VRC4887: A New Antibacterial Agent" VERSICOR
Other presentations on behalf of the industry will be given by Abbott Laboratories, Affinnium Pharmaceuticals, Antex Biologics, Arpida AG, Cetek Corporation, Chiron, Cumbre, Enanta Pharmaceuticals, Essential Therapeutics, Genesoft Pharmaceuticals, Genome Therapeutics, Johnson & Johnson, Nereus Pharmaceuticals, NewBiotics, Novozymes Biotech, Quorex, Rib-X Pharmaceuticals, Sequella, and Versicor, and Wyeth Research. The Scripps Research Institute, Hartford Hospital, and Massachusetts General Hospital will represent academia. |
